Dulaglutide - CISMeF

Preferred Label : Dulaglutide;

NCIt definition : A glucagon-like peptide-1 (GLP-1) receptor agonist that is 90% homologous to native human GLP-1 (7-37) and is composed of a dipeptidyl peptidase-IV-protected GLP-1 analog covalently linked to a human immunoglobulin G4 (IgG4)-Fc heavy chain, with antihyperglycemic activity. Upon administration, dulaglutide binds to and activates GLP-1 receptors, thereby increasing intracellular cyclic AMP (cAMP) in pancreatic beta cells. This increases glucose-dependent insulin release. Dulaglutide also reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying. Altogether this lowers the postprandial glucose level. GLP-1 is normally secreted by L cells of the gastrointestinal (GI) mucosa in response to a meal to normalize blood glucose levels.;

UNII : WTT295HSY5;

CAS number : 923950-08-7;

Drug name : Trulicity;

Molecule name : LY2189265;

NCI Metathesaurus CUI : CL1382408;

Details

Origin ID

C169923;

UMLS CUI

C3179549;

Currated CISMeF NLP mapping
- Dulaglutide [ICD-11 Extension code]
- Dulaglutide [SMS substance]
- Dulaglutide (substance) [SNOMED CT concept]
- dulaglutide [MeSH Supplementary Concept]
- dulaglutide [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Dulaglutide (substance) [SNOMED CT concept]
- Product containing dulaglutide (medicinal product) [SNOMED CT concept]
- dulaglutide [MeSH Supplementary Concept]
- dulaglutide [MeSH concept]
- dulaglutide [ATC Code]
Validated automatic mappings to BTNT
- dulaglutide [ATC Code]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients